CriticalSSRI (selective serotonin reuptake inhibitor)×Antidepressants. Other antidepressants of herbal origin
Updated · Methodology
Mechanism
St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1), and citalopram is a selective serotonin reuptake inhibitor (SSRI). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with SSRIs, including citalopram (St John's wort SmPC, AEMPS, section 4.5). The citalopram SmPC also states that adverse reactions may be more common when citalopram is used with St John's wort (citalopram SmPC, AEMPS, sections 4.4 and 4.5). There is also a second route: hyperforin in St John's wort induces the enzymes CYP3A4, CYP2C9 and CYP2C19, so plasma levels of medicines cleared by these enzymes may fall (St John's wort SmPC, AEMPS, sections 4.5 and 5.2). CYP2C19, CYP3A4 and CYP2D6 take part in citalopram metabolism, but the pharmacokinetic interaction with St John's wort has not been studied (citalopram SmPC, AEMPS, section 4.5).
Symptoms
According to the citalopram label of the US Food and Drug Administration (FDA), St John's wort increases the risk of serotonin syndrome, a potentially life-threatening condition. Signs include mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (tachycardia, labile blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (FDA citalopram label, section 5.3). The Spanish citalopram summary of product characteristics (SmPC) names a combination of symptoms that may indicate the onset of the syndrome: agitation, tremor, myoclonus and hyperthermia (citalopram SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). According to the European Medicines Agency (EMA) herbal monograph, the syndrome occurs very rarely with serotonin reuptake inhibitors (St John's wort herbal monograph, EMA, section 4.5).
Management
The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and its interaction table names citalopram (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The Spanish citalopram SmPC also states that citalopram and St John's wort preparations should not be taken together (citalopram SmPC, AEMPS, section 4.4). If the two have nevertheless been taken together, monitor for signs of serotonin syndrome, particularly at the start of citalopram treatment and after dose increases (citalopram label, US Food and Drug Administration, FDA, section 7). If agitation, tremor, myoclonus and hyperthermia appear, stop citalopram immediately and start symptomatic treatment (citalopram SmPC, AEMPS, section 4.4); the FDA label also says to stop other serotonergic medicines (FDA citalopram label, section 5.3). No document says how long to wait between stopping St John's wort and starting citalopram. Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, European Medicines Agency, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Citalopram, Seropram 30 mg (nº registro 63564) (2024)– AEMPS, CIMA, nº registro 63564 (Seropram 30 mg comprimidos recubiertos con película, Lundbeck), revisión 01/2024, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Celexa (citalopram) – Prescribing Information (2023)– FDA, DailyMed SPL, Allergan, setid 4259d9b1-de34-43a4-85a8-41dd214e9177, version 40, revised 10/2023, sections 4, 5.2, 5.3, 5.4, 7, 12.3 and 17
- AEMPS: Ficha técnica: Hipérico (Hypericum perforatum) (nº registro 79963), secciones 4.3 y 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras, nº registro 79963, documento 11/2025 (fecha de revisión del texto 09/2016), secciones 4.3, 4.4 y 4.5; autorización suspendida desde el 11.06.2026, única ficha técnica de hipérico no revocada en CIMA
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5